VRDN Stock Analysis: Viridian Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.644m USD | 12M Return: 4.3% | US92790C1045 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 40.6M
Qual. Beats: 0
Rev. Trend: 81.5%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a clinical-stage biotechnology company focused on discovering, developing, and commercializing treatments for serious and rare diseases. The companys lead therapeutic area is thyroid eye disease (TED), where it is developing IGF-1R-targeted therapies including Veligrotrug, an intravenously administered humanized monoclonal antibody, and Elegrobart, a subcutaneous, low-volume, and infrequently dosed IGF-1R antibody. Its pipeline also includes an anti-thyroid-stimulating hormone receptor (TSHR) candidate for Graves disease and TED, alongside a portfolio of engineered neonatal Fc receptor (FcRn) inhibitors (VRDN-006 and VRDN-008) designed to suppress IgG-mediated diseases.
The company was originally incorporated in 2010 as Miragen Therapeutics, rebranding to Viridian Therapeutics in January 2021 and is headquartered in Waltham, Massachusetts. As a mid-cap biotechnology company listed on NASDAQ, Viridian operates within a sector characterized by high research and development intensity, reliance on clinical trial outcomes for value creation, and a common strategic focus on rare and underserved diseases-areas that often benefit from orphan drug designation pathways and premium pricing upon approval.
- Veligrotrug Phase 3 TED data readout approaches
- Tepezza competition pressures TED market share outlook
- Cash burn raises dilution risk as pipeline advances
| Net Income: -387.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.30 > 0.02 and ΔFCF/TA 21.94 > 1.0 |
| NWC/Revenue: 1.43k% < 20% (prev 173k%; Δ -171k% < -1%) |
| CFO/TA -0.30 > 3% & CFO -333.3m > Net Income -387.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 16.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (107.9m) vs 12m ago 32.22% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 8.47% > 50% (prev 0.05%; Δ 8.42% > 0%) |
| Interest Coverage Ratio: -19.43 > 6 (EBIT TTM -368.0m / Interest Expense TTM 18.9m) |
| A: 0.93 (Total Current Assets 1.08b - Total Current Liabilities 63.8m) / Total Assets 1.10b |
| B: -1.43 (Retained Earnings -1.57b / Total Assets 1.10b) |
| C: -0.44 (EBIT TTM -368.0m / Avg Total Assets 839.8m) |
| D: 1.52 (Book Value of Equity 662.1m / Total Liabilities 435.1m) |
| Altman-Z'' = 0.07 = B |
| DSRI: 0.10 (Receivables 75.0m/70.0m, Revenue 71.1m/305k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 11.66 (AQ_t 0.01 / AQ_t-1 0.00) |
| SGI: 233.2 (Revenue 71.1m / 305k) |
| TATA: -0.05 (NI -387.0m - CFO -333.3m) / TA 1.10b) |
| Beneish M = 169.0 (Cap -4..+1) = D |
As of November 02, 2026, the stock is trading at USD 24.67 with a total of 1,709,583 shares traded. Over the past week, the price has changed by +10.28%, over one month by +23.38%, over three months by +23.97% and over the past year by +4.27%.
Current recommended Stop Loss: 22.80 (which is 7.6% or 1.9 ATR below the current price).
Viridian Therapeutics has received a consensus analysts rating of 4.82. Therefore, it is recommended to buy VRDN.
- StrongBuy: 14
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 36.2 | 46.7% |
P/E Forward = 1.0072
P/S = 37.1763
P/B = 4.4919
Revenue TTM = 71.1m USD
EBIT TTM = -368.0m USD
EBITDA TTM = -367.6m USD
Long Term Debt = 242.2m USD (from longTermDebt, last quarter)
Short Term Debt = 722k USD (from shortTermDebt, last quarter)
Debt = 243.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 722k
Net Debt = -661.4m USD (calculated: Debt 243.6m - CCE 905.0m)
Enterprise Value = 1.98b USD (2.64b + Debt 243.6m - CCE 905.0m)
Interest Coverage Ratio = -19.43 (Ebit TTM -368.0m / Interest Expense TTM 18.9m)
EV/FCF = -5.93x (Enterprise Value 1.98b / FCF TTM -334.6m)
FCF Yield = -16.87% (FCF TTM -334.6m / Enterprise Value 1.98b)
FCF Margin = -470.4% (FCF TTM -334.6m / Revenue TTM 71.1m)
Net Margin = -544.1% (Net Income TTM -387.0m / Revenue TTM 71.1m)
Gross Margin = unknown ((Revenue TTM 71.1m - Cost of Revenue TTM 1.16m) / Revenue TTM)
Tobins Q-Ratio = 1.81 (Enterprise Value 1.98b / Total Assets 1.10b)
Interest Expense / Debt = 7.77% (Interest Expense 18.9m / Debt 243.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -290.7m (EBIT -368.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 14.93 (Total Current Assets 1.08b / Total Current Liabilities 72.4m)
Debt / Equity = 0.37 (Debt 243.6m / totalStockholderEquity, last quarter 662.1m)
Debt / EBITDA = 1.80 (negative EBITDA) (Net Debt -661.4m / EBITDA -367.6m)
Debt / FCF = 1.98 (negative FCF - burning cash) (Net Debt -661.4m / FCF TTM -334.6m)
Total Stockholder Equity = 630.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -46.08% (Net Income -387.0m / Total Assets 1.10b)
RoE = -61.35% (Net Income TTM -387.0m / Total Stockholder Equity 630.8m)
RoCE = -42.16% (EBIT -368.0m / Capital Employed (Equity 630.8m + L.T.Debt 242.2m))
RoIC = -28.21% (negative operating profit) (NOPAT -290.7m / Invested Capital 1.03b)
WACC = 7.51% (E(2.64b)/V(2.89b) * Re(7.64%) + D(243.6m)/V(2.89b) * Rd(7.77%) * (1-Tc(0.21)))
Discount Rate = 7.64% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.72 | Cagr: 28.75%
[DCF] Fair Price = unknown (Cash Flow -334.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.37 | # QB: 0
Revenue Correlation: 81.50 | Revenue CAGR: 1.03k% | SUE: 0.01 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-1.02 | Chg30d=-3.49% | Revisions=+25% | Analysts=11
EPS current Year (2026-12-31): EPS=-3.94 | Chg30d=+0.17% | Revisions=+25% | GrowthEPS=-18.7% | GrowthRev=-65.6%
EPS next Year (2027-12-31): EPS=-2.75 | Chg30d=+0.66% | Revisions=+25% | GrowthEPS=+30.1% | GrowthRev=+858.2%
[Analyst] Revisions Ratio: +50% (up=3, down=0)